Selecta Biosciences, Inc.

Selecta Biosciences, Inc.

Selecta Biosciences, Inc.

Overview
Date Founded

2007

Headquarters

65 Grove Street,Watertown, MA 02472

Type of Company

Public

Employees (Worldwide)

39

Industries

Biotechnology

Company Description

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Contact Data
Trying to get in touch with decision makers at Selecta Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Chief Operations Officer

Chief Scientific Officer

Chief Medical Officer

Managing Director, Selectarus, LLC

Controller

Financial Controller

Offc Manager

Board of Directors

Executive Chairman at Humacyte, Inc.

Former Executive Chairman of the Board & Interim Chief Executive Officer at EXACT Sciences Corp.

Founder at Morphic Therapeutic, Inc.

Former Executive Vice President & Chief Financial Officer at Affymetrix, Inc.

Former President & Chief Executive Officer at AMAG Pharmaceuticals, Inc.

President & Chief Executive Officer at Selecta Biosciences, Inc.

MD at Essex Woodlands Management, Inc.

Founder & Managing Partner at NanoDimension Management Ltd.

Paths to Selecta Biosciences, Inc.
Potential Connections via
Relationship Science
You
Selecta Biosciences, Inc.
Owners & Shareholders
Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health.MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research

Details Hidden

Endurant Capital Management seeks to generate steady, risk-adjusted returns through long/short investments in small- to mid-cap growth companies in the healthcare sector. The firm’s fund and sub-advised accounts invest principally, but not solely, in equity and equity-related securities that are traded publicly in US markets.

Recent Transactions
Details Hidden

Selecta Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Selecta Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Selecta Biosciences, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Escrow Agent

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Investment Advisor

Advised onSelecta Biosciences, Inc. raised money in a private placement transaction

Managing Director

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Legal Advisor

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Latham & Watkins LLP

Advisor

Former General Manager-Pharmaceuticals at Solvay SA

Consultant

Former Chief Financial Officer & Treasurer at Selecta Biosciences, Inc.

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.

Key Stats and Financials As of 2019
Market Capitalization
$514M
Total Enterprise Value
$37.5M
Earnings Per Share
$-1.22
Revenue
$6.68M
Net Profit
$-55.4M
EBITDAMargin
-755.25%
EBITDA
$-50.4M
Total Equity
$8.4M
Total Debt
$19.3M
TEVNet Income
-0.68x
Enterprise Value / Sales
5.62x
Debt TEV
0.51x
Three Year Compounded Annual Growth Rate Of Revenue
-6.17%
Non-Profit Donations & Grants Received
Investors
Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

Founder at Morphic Therapeutic, Inc.

Suppliers
3SBio, Inc. Biotechnology | Shenyang, China

3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.

Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sangamo Therapeutics, Inc. Biotechnology - Brisbane, CA

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Sangamo was founded in 1995, went public in 2000, and trades on the Nasdaq Global Market (SGMO). We are located in Richmond, California, in the Bay Area, the birthplace of biotechnology. We are intimately involved in our community through partnerships with academic institutions, relationships with non-profit organizations and ties to advocacy organizations aligned with improving the quality of life for patients with unmet medical needs within our strategic vision.

Awards & Honors
2014
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Selecta Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Selecta Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Selecta Biosciences, Inc..